Cited by

• Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies.

  Mainieri F, La Bella S, Rinaldi M, Chiarelli F. Mainieri F, et al. Eur J Pediatr. 2024 Apr;183(4):1499-1508. doi: 10.1007/s00431-024-05427-4. Epub 2024 Jan 16. Eur J Pediatr. 2024. PMID: 38227053 Review.
• Incretin-based therapies for liver disease.

  Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):533. doi: 10.1038/s41575-024-00961-w. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38977817 No abstract available.
• Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

  Do A, Zahrawi F, Mehal WZ. Do A, et al. Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28. Nat Rev Drug Discov. 2025. PMID: 39609545 Review.
• The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats.

  Goldberg M, Blevins JE, Wolden-Hanson T, Elfers CT, Chichura KS, Ashlaw EF, den Hartigh LJ, Roth CL, Doyle RP. Goldberg M, et al. Int J Mol Sci. 2025 Mar 26;26(7):3032. doi: 10.3390/ijms26073032. Int J Mol Sci. 2025. PMID: 40243702 Free PMC article.
• The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk.

  Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, Hitos AB, Field J, Francisco V, Escalona-Garrido C, Zagmutt S, Calderon-Dominguez M, Mera P, Garcia-Martinez I, Maymó-Masip E, Grajales D, Alen R, Mora A, Sáinz N, Vides-Urrestarazu I, Vilarrasa N, Arbones-Mainar JM, Zaragoza C, Moreno-Aliaga MJ, Aspichueta P, Fernández-Veledo S, Vendrell J, Serra D, Herrero L, Schreiber R, Zechner R, Sabio G, Hornigold D, Rondinone CM, Jermutus L, Grimsby J, Valverde ÁM. Valdecantos MP, et al. Nat Commun. 2024 Nov 28;15(1):10342. doi: 10.1038/s41467-024-54080-w. Nat Commun. 2024. PMID: 39609390 Free PMC article.